Table 7.

Sequential WOMAC Total – Summary

Group	Baseline	Week 1	Week 2	Week 4	Week 6	Week 8
Placebo	48.6 ± 5.2	49.0 ± 5.8	46.6 ± 5.9	43.5 ± 5.8	38.8 ± 5.9 *	35.3 ± 6.3 **
A	51.5 ± 6.4	43.5 ± 6.9	41.4 ± 6.7 **	35.0 ± 6.2 ***	36.2 ± 6.2 ***	31.8 ± 6.1 ***
B	46.4 ± 5.6	42.0 ± 5.9 *	38.6 ± 6.0 ***	32.6 ± 5.2 ***	31.5 ± 5.3 ***	28.5 ± 3.9 ***
C	44.8 ± 5.5	42.3 ± 5.2	39.0 ± 5.1 **	32.0 ± 4.4 ***	28.7 ± 4.5 ***	25.6 ± 4.4 ***

Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, ** p < 0.001. Note the p values for groups A and C approached significance at week one (p = 0.051 and 0.053).